DEVELOPMENT AND VALIDATION OF A SELECTIVE ELECTRO SPRAY IONIZATION – LIQUID CHROMATOGRAPH TANDEM MASS SPECTROMETRY METHOD FOR SIMULTANEOUS DETERMINATION OF SEMAGLUTIDE AND EMPAGLIFLOZIN IN HUMAN PLASMA
DOI:
https://doi.org/10.22159/ajpcr.2026v19i1.56485Keywords:
Semaglutide, Empagliflozin, Electro Spray Ionization, Method validation, Mass SpectrometerAbstract
Objective: The objective of the study was to develop a method capable of simultaneously estimating semaglutide and empagliflozin used in combination for treating Diabetes.
Methods: A structured protein precipitation extraction technique was used for the estimation of semaglutide and empagliflozin. The two compounds were separated on a Zorbax C18 (50 mm × 2.1 mm, 5 μ Particle size) column, with a positive polarity Electro Spray Ionization on a Liquid chromatograph with Tandem Mass Spectrometry instrument. Verapamil was employed as an internal standard for this estimation, which was carried out through a multiple reaction monitoring method and a gradient program utilizing acetonitrile and 0.1% formic acid in water as mobile phases to achieve a separation in 2.5 min.
Results: The method established was performing linearly over a working range of 1.00–1000 ng/mL for semaglutide (r2>0.98) and 0.51–500 ng/mL for empagliflozin (r2>0.98) in human plasma. The validation parameters, including specificity, selectivity, precision, accuracy, recovery, matrix effects and stability, were within acceptable limits. The stability was established in compliance with the International Council for Harmonization guideline M10 on Bioanalytical method validation.
Conclusion: This method was selective and with suitable sensitivity at the 1.00 ng/mL and 0.50 ng/mL Lower Limit of Quantification employed for semaglutide and empagliflozin. It can be utilized for estimation in human plasma and will facilitate further application to bioequivalence and exploratory formulation studies for the combination of these two drugs in pharmaceutical dosage forms
Downloads
References
1. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Sep 15;375(19):1834-44. doi: 10.1056/ NEJMoa1607141, PMID 27633186
2. Goldenberg RM, Steen O. Semaglutide: Review and place in therapy for adults with type 2 diabetes. Can J Diabetes. 2019 Jun 5;43(2):136-45. doi: 10.1016/j.jcjd.2018.05.008, PMID 30195966
3. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem. 2003;278(1):471-8. doi: 10.1074/jbc.M209423200, PMID 12409292
4. Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne). 2021;12:645617. doi: 10.3389/ fendo.2021.645617, PMID 34248838, PMCID PMC8269445
5. Jensen L, Helleberg H, Roffel A, Van Lier JJ, Bjørnsdottir I, Pedersen PJ, et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. Eur J Pharm Sci. 2017;104:31-41. doi: 10.1016/j.ejps.2017.03.020, PMID 28323117
6. Marbury TC, Flint A, Jacobsen JB, DervingKarsbøl J, Lasseter K. Pharmacokinetics and tolerability of a single dose of semaglutide, a human glucagon-like peptide-1 analog, in subjects with and without renal impairment. Clin Pharmacokinet. 2017;56(11):1381-90. doi: 10.1007/ s40262-017-0528-2, PMID 28349386, PMCID PMC5648736
7. Overgaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: Analyses of data from clinical pharmacology trials. Clin Pharmacokinet. 2021;60(10):1335-48. doi: 10.1007/s40262-021-01025-x, PMID 33969456, PMCID PMC8505367
8. Jensen L, Kupcova V, Arold G, Pettersson J, Hjerpsted JB. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes Obes Metab. 2018;20(4):998-1005. doi: 10.1111/ dom.13186, PMID 29205786, PMCID PMC5873441
9. Baekdal TA, Thomsen M, Kupčová V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314-23. doi: 10.1002/jcph.1131, PMID 29693715, PMCID PMC6175428
10. Kute SA, Chothave MS, Rote PB, Kapadnis AA, Kale VV. Exploring the unintended consequences of misuse of wegovy and ozempic in weight management: A comprehensive review. Int J Pharm Pharm Sci. 2024;16(6):10-3.
11. Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, et al. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:123688. doi: 10.1016/j.jchromb.2023.123688, PMID 36989942
12. Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/ levonorgestrel. J Clin Pharmacol. 2015;55(5):497-504. doi: 10.1002/ jcph.443, PMID 25475122, PMCID PMC4418331
13. Gumieniczek A, Berecka A. Analytical tools for determination of new oral antidiabetic drugs, glitazones, gliptins, gliflozins and glinides, in bulk materials, pharmaceuticals, and biological samples. Open Chem. 2016;14(1):215-42.
14. DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. doi: 10.1038/nrdp.2015.19, PMID 27189025
15. Scheen AJ, Paquot N. Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39(3):179-90. doi: 10.1016/j.diabet.2013.02.006, PMID 23528671
16. Sarkar S, Sadhu S, Roy R, Tarafdar S, Mukherjee N, Sil M, et al. Contemporary drifts in diabetes management. Int J App Pharm. 2023;15(2):1-9.
17. Van Der Aart-Van Der Beek AB, Wessels AM, Heerspink HJ, Touw DJ. Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Sep 1;1152:122257. doi: 10.1016/j.jchromb.2020.122257, PMID 32663790
18. Ayoub BM, Mowaka S. LC-MS/MS determination of empagliflozin and metformin. J Chromatogr Sci. 2017;55(7):742-7. doi: 10.1093/ chromsci/bmx030
19. ICH. Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis. United States: ICH; 2023.
20. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75(13):3019-30. doi: 10.1021/ ac020361s, PMID 12964746
Published
How to Cite
Issue
Section
Copyright (c) 2025 Jagapathi Raju Vatsavayi, R Baby Nalanda
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.